Metabolism of ticagrelor in patients with acute coronary syndromes

Ticagrelor is a state-of-the-art antiplatelet agent used for the treatment of patients with acute coronary syndromes (ACS). Unlike remaining oral P2Y12 receptor inhibitors ticagrelor does not require metabolic activation to exert its antiplatelet action. Still, ticagrelor is extensively metabolized...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Sci Rep
Autori principali: Adamski, Piotr, Buszko, Katarzyna, Sikora, Joanna, Niezgoda, Piotr, Barańska, Malwina, Ostrowska, Małgorzata, Paciorek, Przemysław, Navarese, Eliano P., Gorog, Diana A., Kubica, Jacek
Natura: Artigo
Lingua:Inglês
Pubblicazione: Nature Publishing Group UK 2018
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6078957/
https://ncbi.nlm.nih.gov/pubmed/30082687
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-018-29619-9
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi